Morgan Stanley raised the firm’s price target on AstraZeneca (AZN) to 16,500 GBp from 16,000 GBp and keeps an Overweight rating on the shares, calling the stock a Top Pick. Morgan Stanley cited “FX updates and recent positive pipeline developments” for its price target raise. The firm updated its model on the company ahead of Q1 earnings results, saying it sees Q1 group sales coming in ~1% above consensus, driven by Oncology and CVRM.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Compugen initiated with a Buy at Lake Street
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- AstraZeneca Completes Early Obesity Trial for AZD6234, Nudging Long-Term Growth Hopes
- AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?
- White House says imposing tariffs on patented pharmaceutical products